34th Annual Pittsburgh Schizophrenia Conference

34th Annual Pittsburgh Schizophrenia Conference

Lisa Beth Dixon, MD, MPH
Professor of Psychiatry
Columbia University Medical Center   
November 3, 2017 - 7:30am
Sheraton Station Square, Pittsburgh

34th Annual Pittsburgh Schizophrenia Conference

Join us for the Pittsburgh Schizophrenia Conference at the Sheraton Station Square. This annual meeting highlights the advances in schizophrenia research and features experts in the field. Topics at this year’s meeting include: neuroimaging in schizophrenia and how it applies to clinical practice, the use of herbal botanical medicines in the treatment of schizophrenia and an afternoon panel that comprises psychiatrists, clinicians and individuals receiving services who speak to the post-hospital care they receive and how these may assist in their integration into the community.

Gerard E. Hogarty Excellence in Schizophrenia Research Memorial Lecture

Lisa Beth Dixon, MD, MPH
 Professor of Psychiatry
 Columbia University Medical Center 
 Director, Division of Mental Health Services
   and Policy Research 
 Director, Center for Practice Innovations
 New York State Psychiatric Institute

The conference is designed to disseminate the latest research findings to a wide audience: psychiatrists and other mental health clinicians, including nurses, social workers, psychologists, service coordinators, researchers, patients and their relatives, mental health policy administrators and others who intend to keep current regarding etiologic and treatment research in schizophrenia.

Our conference brochure provides a detailed schedule, registration instructions, and information on continuing education credits. Visit this link to register online.

Learning Objectives. At the conclusion of the program, participants should be able to:

Explain the rationale for using a standardized extract of Withania somnifera as adjunctive treatment for persons with schizophrenia experiencing break through symptoms.
Evaluate the data and results of a randomized double-blind, placebo-controlled clinical trial that evaluated this herbal medication.
Review key findings related to the prefrontal cortex in schizophrenia.
Recognize recent work that utilizes functional connectivity to understand schizophrenia.
Identify the reduction of certain brainwaves in persons with schizophrenia.
Explain how neuro-inflammation and oxidative stress may impair cortical function.

For more information regarding the conference, please contact Nancy Mundy (Telephone: 412-204-9090; Email: mundynl@upmc.edu).